Skip to content
value.today

Sanuwave Health, Inc.

SNWV
$44 Mmarket cap on Oct 28, 2026
Compare
World rank
#21,708
Revenue
$44 M
For year ending December-2025
Net income
$12 M
26.8% margin
SEC filing
Employees
55
As of December 31, 2025
SEC filing

Sanuwave Health, Inc. in brief

Sanuwave Health, Inc. is a listed company in the Medical Devices industry, based in Georgia, USA. Its market value was $44 M on 28 October 2026, which makes it the 21,708th largest listed company in the world and the 3,911th largest in the USA on this site. In the year to December 2025 it had sales of $44 M and a net profit of $12 M, about 27 cents of profit for every dollar of sales. It employs about 55 people and Morgan C. Frank is its chief executive. Its largest product and service lines by sales in 2025 were Consumables, parts, and accessories revenue (59%), System revenue (41%) and Extended warranty (under 1%). Its shares trade under the symbol SNWV (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Sanuwave Health, Inc.

Sanuwave is a medical device company providing directed energy products into the wound care space. Our mission is to improve patient lives and outcomes by developing and marketing effective, easy to use products to decrease wound burden, lessen healing times, and reduce patient pain.

Our focus is regenerative medicine utilizing noninvasive ultrasound to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The Company’s patented and FDA cleared product is the UltraMIST® system, which is used to treat a variety of acute and chronic wounds. The Company is backed by an intellectual property portfolio of over 60 patents.

From the company's annual report filed with the US SEC: read the report

Sanuwave Health, Inc. timeline

3 events, 2007–2025
  1. 2007
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2010
  4. ✎
    Renamed SANUWAVE Health, Inc.
    Formerly Rub Music Enterprises, Inc..
  5. 2025
  6. 💰
    Record revenue of $44 million
    FY2025, the highest of the 8 years on record.

Events of Sanuwave Health, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$54 M$107 M$161 M$215 M2023202420252026

World rank over time

▲ up 3,417 places since 2022
2022-01-07: #25172#25,17220222026-03-08: #8992#8,99220262026-08-01: #19963#19,96320262026-10-08: #21539#21,53920262026-10-28: #21755#21,7552026

Rank in USA: #4,662 (Jan 2022) · #1,710 (Mar 2026) · #3,795 (Aug 2026) · #3,862 (Oct 2026) · #3,915 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
10.6×
Price / sales (TTM)
1.1×
Price / book
27.2×
Free cash flow yield
4.4%
Net margin (TTM)
10.0%
Operating margin
11.2%
Return on equity
256.2%
Liabilities / assets
95.7%
Net debt
$10M
Revenue growth
+35.0%
R&D / revenue
3.1%
Revenue per employee
$801 K
Profit per employee
$215 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-12M$2MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-10M$2MFY19Fiscal year ending Dec 2020: revenue $4M, net income $-31M$4MFY20Fiscal year ending Dec 2021: revenue $13M, net income $-27M$13MFY21Fiscal year ending Dec 2022: revenue $17M, net income $-10M$17MFY22Fiscal year ending Dec 2023: revenue $20M, net income $-26M$20MFY23Fiscal year ending Dec 2024: revenue $33M, net income $-33M$33MFY24Fiscal year ending Dec 2025: revenue $44M, net income $12M$44MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$44M+35.0%$5M$12M26.8%
Dec 2024$33M+60.0%$4M$-33M-101.4%
Dec 2023$20M+21.9%$-1M$-26M-126.5%
Dec 2022$17M+28.7%$-9M$-10M-61.5%
Dec 2021$13M+220.4%$-14M$-27M-209.5%
Dec 2020$4M+165.4%$-25M$-31M-762.1%
Dec 2019$2M-17.3%$-9M$-10M-681.7%
Dec 2018$2M—$-7M$-12M-628.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$4M$2M$2M$0.41—
Dec 2024$2M$0M$2M$-7.41—
Dec 2023$-5M$0M$-5M$-12.19—
Dec 2022$-17M——$-0.02—
Dec 2021$-6M$1M$-7M$-0.05—
Dec 2020$-13M$0M$-13M$-0.08—
Dec 2019$-6M$0M$-6M$-0.05—
Dec 2018$-4M$0M$-4M$-0.08—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$41M
Net income, trailing 12 months
$4M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $10M, net income $-13M$10MDec ’24Three months to Mar 2025: revenue $9M, net income $-6M$9MMar ’25Three months to Jun 2025: revenue $10M, net income $1M$10MJun ’25Three months to Sep 2025: revenue $11M, net income $10M$11MSep ’25Three months to Dec 2025 (from the annual report): revenue $13M, net income $8M$13MDec ’25Three months to Mar 2026: revenue $10M, net income $-1M$10MMar ’26Three months to Jun 2026: revenue $10M, net income $-1M$10MJun ’26Three months to Sep 2026: revenue $9M, net income $-1M$9MSep ’26

Latest quarter to Sep 2026: revenue $9M (-23.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Sanuwave Health, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$44 M
Operating income
$5 M
Net income
$12 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$37 M
Total liabilities
$36 M
Total equity
$2 M

As of December-2025

Top 40 institutional investors in Sanuwave Health, Inc.#

As of Sep 30, 2026
40 institutions held 2.6 M shares (about 30.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 26.3%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Sanuwave Health, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Solas Capital Management, LLC610,9680 (0.00%)7.10%$3 MNov 16, 2026
2AWM Investment Company, Inc.427,765-26,785 (-5.89%)4.97%$2 MNov 13, 2026
3Vanguard Capital Management LLC348,050-4,706 (-1.33%)4.05%$2 MNov 13, 2026
4Opaleye Management Inc.306,1400 (0.00%)3.56%$1 MNov 16, 2026
5UBS Group AG162,089-94,702 (-36.88%)1.88%$1 MNov 10, 2026
6BlackRock, Inc.142,973-16,894 (-10.57%)1.66%$1 MNov 13, 2026
7Geode Capital Management, LLC89,704+3,606 (+4.19%)1.04%$0 MNov 6, 2026
8D. E. Shaw & Co., Inc.59,338New0.69%$0 MNov 16, 2026
9Luxor Capital Group, LP58,299+21,099 (+56.72%)0.68%$0 MNov 16, 2026
10Vanguard Fiduciary Trust Co54,862+11,765 (+27.30%)0.64%$0 MNov 13, 2026
11Jpmorgan Chase & Co50,107+10,410 (+26.22%)0.58%$0 MNov 12, 2026
12State Street Corp31,282-1,000 (-3.10%)0.36%$0 MNov 12, 2026
13Morgan Stanley30,446-1,173 (-3.71%)0.35%$0 MNov 13, 2026
14XTX Topco Ltd29,282+7,448 (+34.11%)0.34%$0 MNov 16, 2026
15Gsa Capital Partners LLP28,452New0.33%$0 MNov 16, 2026
16State of Alaska, Department of Revenue28,235+25,000 (+772.80%)0.33%$0 MOct 15, 2026
17Invesco Ltd.25,573New0.30%$0 MNov 12, 2026
18Goldman Sachs Group Inc24,583-15,843 (-39.19%)0.29%$0 MNov 16, 2026
19Citadel Advisors LLC23,050-36,423 (-61.24%)0.27%$0 MNov 16, 2026
20Squarepoint Ops LLC21,243+3,000 (+16.44%)0.25%$0 MNov 9, 2026
21Bank Of America Corp /de/18,570+11 (+0.06%)0.22%$0 MNov 16, 2026
22Northern Trust Corp16,4540 (0.00%)0.19%$0 MNov 16, 2026
23BNP Paribas Financial Markets15,019+1,715 (+12.89%)0.17%$0 MNov 12, 2026
24Millennium Management LLC10,282-6,643 (-39.25%)0.12%$0 MNov 16, 2026
25Praetorian PR LLC8,453-386,547 (-97.86%)0.10%$0 MNov 16, 2026
Show all 40: investors 26 to 40
Institutional investors 26 to 40 in Sanuwave Health, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Cullinan Associates Inc4,200New0.05%$0 MNov 3, 2026
27Vanguard Global Advisers, LLC3,2370 (0.00%)0.04%$0 MNov 13, 2026
28FMR LLC2,849-1,605 (-36.04%)0.03%$0 MNov 10, 2026
29Russell Investments Group, Ltd.2,327+2,278 (+4648.98%)0.03%$0 MNov 6, 2026
30Strategic Investment Solutions, Inc. /IL1,3330 (0.00%)0.02%$0 MNov 12, 2026
31Acuitas Investments, LLC1,000New0.01%$0 MNov 6, 2026
32Royal Bank Of Canada413+264 (+177.18%)0.00%$0 MNov 16, 2026
33WealthCollab, LLC410New0.00%$0 MNov 12, 2026
34ABS Investment Management LLC400New0.00%$0 MNov 16, 2026
35Arax Advisory Partners291-355 (-54.95%)0.00%$0 MNov 12, 2026
36Physician Wealth Advisors, Inc.245New0.00%$0 MOct 20, 2026
37US Bancorp \de\660 (0.00%)0.00%$0 MNov 5, 2026
38NewEdge Advisors, LLC260 (0.00%)0.00%$0 MNov 13, 2026
39Osaic Holdings, Inc.120 (0.00%)0.00%$0 MNov 12, 2026
40IFP Advisors, Inc10 (0.00%)0.00%$0 MOct 16, 2026

Mutual funds holding Sanuwave Health, Inc.#

33 funds hold shares worth $6 M (about 8.1% of the company). Since their previous reports 16 added shares and 42 sold, selling $7 M net.
Mutual funds holding Sanuwave Health, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.264,933$3 M4.0%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.78,885$1 M1.2%<0.01%+5.2%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.38,422$1 M0.58%<0.01%+4.8%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC36,377$1 M0.55%<0.01%−1.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors26,001$0 M0.39%0.02%+39%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,580$0 M0.20%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,764$0 M0.16%<0.01%+7.4%May 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.9,750$0 M0.15%0.02%+1.3%May 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.7,105$0 M0.11%<0.01%+3.0%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC10,000$0 M0.15%0.07%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.9,271$0 M0.14%<0.01%+141%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC5,459$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,706$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company2,852$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.4,232$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC3,564$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,747$0 M0.03%<0.01%+25%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION1,000$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC2,389$0 M0.04%<0.01%−0.3%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,432$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.611$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC1,454$0 M0.02%<0.01%+41%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC350$0 M<0.01%<0.01%+8.4%May 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.940$0 M0.01%<0.01%+1.8%Jul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC501$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC300$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC274$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC276$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC230$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC271$0 M<0.01%<0.01%−57%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC175$0 M<0.01%<0.01%+12%Jun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC171$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC46$0 M<0.01%<0.01%+4.5%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 33 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Sanuwave Health, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$7.2 M
17 sales, 3 insiders
Net, 12 months
-$7.2 M
open market only
Insiders on file
19
since
$1.7 M-$5.0 M$0Oct 2024: bought $1.7 M (4 trades), sold $0 (0 trades)Oct 24Nov 2024: bought $243 K (2 trades), sold $0 (0 trades)Apr 2025: bought $204 K (2 trades), sold $0 (0 trades)AprMay 2025: bought $0 (0 trades), sold $115 K (1 trades)Jun 2025: bought $0 (0 trades), sold $52 K (1 trades)JunOct 2025: bought $38 K (1 trades), sold $0 (0 trades)Dec 2025: bought $0 (0 trades), sold $5.0 M (6 trades)DecApr 2026: bought $0 (0 trades), sold $2.0 M (9 trades)May 2026: bought $0 (0 trades), sold $170 K (2 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Sanuwave Health, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Opaleye Management Inc.10% ownerSellindirect-10,081$16.11$162 K853,569Form 4
filed Opaleye Management Inc.10% ownerSellindirect-500$16.11$8 K5,000Form 4
filed Opaleye Management Inc.10% ownerSellindirect-24,000$16.15$388 K863,650Form 4
filed Opaleye Management Inc.10% ownerSellindirect-1,000$16.15$16 K5,500Form 4
filed Opaleye Management Inc.10% ownerSellindirect-23,360$17.25$403 K887,650Form 4
filed Opaleye Management Inc.10% ownerSellindirect-1,000$17.25$17 K6,500Form 4
filed Opaleye Management Inc.10% ownerSellindirect-43,788$18.47$809 K911,010Form 4
filed Opaleye Management Inc.10% ownerSellindirect-2,500$18.47$46 K7,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Sanuwave Health, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
180,212
2.1% of shares · 5.76 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-370.37 reverse split

Trading halts

  • 2026-11-05 14:56 UTC, code LUDP, resumed 15:06 UTC
  • 2026-11-05 14:41 UTC, code LUDP, resumed 14:51 UTC
  • 2026-11-05 14:31 UTC, code LUDP, resumed 14:36 UTC

Fails to deliver

  • : 12 shares at $5.13
  • : 15 shares at $5.54
  • : 65 shares at $4.10
  • : 45 shares at $4.45
  • : 970 shares at $5.03

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sanuwave Health, Inc. scorecard#

Passes 15 of the 22 checks that could be worked out: strongest in growth (6 of 6), weakest in financial health (2 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation3 of 5
    • ✓P/E below its peers' median10.6×P/E 10.6× against Medical Devices's median of 24.1×.
    • ✗Price to book below its peers' median27.2×Price to book 27.2× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median1.1×Price to sales 1.1× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%4.4%Free cash flow is 4.4% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield9.4%Earnings yield 9.4% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth6 of 6
    • ✓Revenue grew in the newest year35.0%Revenue up 35.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years38.1%38.1% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median38.1%38.1% a year against Medical Devices's median of 10.8% (73 companies).
    • ✓Earnings per share grew in the newest year0.41 vs -7.41Diluted EPS 0.41 in fiscal 2025 against -7.41 the year before (report's currency).
    • ✓Net income higher than five years earlier$12 M$12 M in fiscal 2025 against -$31 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability4 of 5
    • ✓Profitable in the newest year$12 MNet income $12 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median11.2%11.2% against Medical Devices's median of -8.2% (86 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • ✓Return on invested capital above 10%42.5%42.5% in fiscal 2025.
    • ✓Operating margin wider than three years earlier11.2%11.2% in fiscal 2025 against -53.5% in 2022.
  • Financial health2 of 5
    • ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.38 at the end of fiscal 2025.
    • ✗Debt below equity13.5×Debt to equity 13.51 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDA1.7×Net debt 1.7 times EBITDA in fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.52Z-score -6.52 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year103.5%Diluted shares up 103.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Sanuwave Health, Inc.'s statements, beside the median of Medical Devices.

Sanuwave Health, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin11.2%-8.2%
Net margin26.8%-10.4%
Revenue growth, 3 years a year38.1%10.8%
Revenue growth35.0%10.4%
Debt to equity13.51×0.64×
Free cash flow margin4.4%-1.9%

6of 8on the Piotroski tests of financial strength

  • Only 33% of net income arrived as cash from operations.
  • The share count rose 103.5% in the year.
  • Receivables grew 63% while revenue grew 35%: customers are paying later, or sales were booked ahead of cash.
  • Goodwill and intangibles ($10 million) exceed shareholders' equity ($2 million).

Sanuwave Health, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sanuwave Health, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue44332017134.1r1.51.90.71.4
Cost of revenue108.16.04.35.01.2r0.50.70.20.6
Gross profit342514128.02.9r0.5r1.20.5—
Research and development1.40.70.60.61.11.2r1.21.0r1.31.1
Selling and marketing7.46.34.97.58.65.2r1.60.5——
General and administrative1913r8.7131214r6.46.8r3.02.7
Operating expenses2921r15212228r9.38.34.34.1
Total costs and expenses0.60.50.50.30.4—————
Operating income4.93.8r−0.5−9.0−14−25r−8.8r−7.2−3.8−3.3
Interest expense and finance costs—13—136.92.0r1.84.51.1r0.9
Other non-operating income (expense)7.0−37r−25−1.3−13−5.7r−1.6−4.5−1.7−3.1
Income before tax12−33————————
Income tax0.10.00.00.00.000000
Net income attributable to shareholders12−33r−26−10−27−31r−10r−12−5.5−6.4
Earnings per share, basic1.38-7.41r-12.19r-0.02-0.05-0.08-0.05-0.08-0.04-0.06
Earnings per share, diluted0.41-7.41r-12.19r-0.02-0.05-0.08-0.05-0.08-0.04-0.06
Shares, weighted average (basic)8.64.52.1r549518378204———
Shares, weighted average (diluted)9.14.52.1r549518378204r150139108
Balance sheet
Cash and cash equivalents12101.81.20.62.4r1.80.40.70.1
Receivables5.43.33.34.02.42.4r0.10.20.20.5
Inventory5.94.13.00.91.03.0r0.50.40.20.2
Other current assets1.30.71.70.60.30.2r0.1———
Current assets25189.86.64.47.9r2.51.11.20.9
Property, plant and equipment2.00.3r0.90.9r1.0r0.5r0.1r0.10.10.1
Right-of-use (leased) assets0.40.4——0.20.4r0.5r0——
Goodwill7.37.37.37.37.37.3r0———
Other intangible assets3.03.74.45.15.86.5————
Non-current assets1312131314—————
Total assets373022201923r3.41.21.31.0
Accounts payable3.33.75.74.47.64.5r1.41.61.50.7
Debt due within a year5.8———2517————
Current liabilities1845r6560r5636r12r1611r7.9
Long-term debt16———0.90.1————
Lease liabilities (non-current)0.9———0.10.2r0.20——
Non-current liabilities180.50.80.7r1.30.6r1.0r0.00—
Total liabilities3646r66615837r13r1711r7.9
Retained earnings−243−254r−220−194−184−157r−126r−117−105r−99
Shareholders' equity1.6−16r−45r−41−39−14r−10r−15−9.9r−6.9
Total liabilities and equity373022201923r3.41.21.31.0
Shares outstanding8.68.53.0r549482471294156139137
Cash-flow statement
Depreciation and amortization1.00.8r1.01.01.2r0.3r0.1———
Share-based compensation4.91.50—00.0r0.32.50.80.5
Cash from operating activities3.92.5−4.5−17−6.4−13r−6.4−3.6−1.5−3.2
Capital expenditure−1.9−0.50—−0.5−0.1r−0.1−0.00−0.0
Cash from investing activities3.4−0.50.00.3−0.5−20r−0.1−0.00−0.0
Debt repaid——0−3.0−0.5−5.5r0———
Shares issued0100———————
Cash from financing activities−5.66.45.2175.133r7.93.32.13.2
Exchange-rate effect on cash00.1−0.1−0.0−0.00r0.0−0.00.0−0.0
Change in cash1.78.40.60.5−1.80.7r1.4−0.40.6−0.0
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Sanuwave Health, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Consumables, parts, and accessories revenue$26 M59%
  • System revenue$18 M41%
  • Other$0 M0.5%
  • Extended warranty$0 M0.4%
  • License fees$0 M0.1%

Business segments

  • Reportable$44 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Sanuwave Health, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$414 K
Morgan C. Frank
Other top executives, average
$1.3 M
the CEO earned 0.3× this
$100 invested is now
$349
Sanuwave Health, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Morgan C. Frank$414 K$1.6 M$1.3 M$349
2024Morgan C. Frank$1.4 M$2.6 M$1.0 M$269
2023Morgan C. Frank$410 K$410 K$329 K$57

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Sanuwave Health, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Financial statements withdrawnFiling
  • Auditor changedFiling
  • Auditor changedFiling
  • Auditor changedFiling

Delisting notice 1 · Financial statements withdrawn 1 · Auditor changed 3 · Directors and officers 6 · Material agreement 3 · Agreement ended 1 · New debt 1 · Shareholder vote 3 · Results announced 12

Sanuwave Health, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Financial statements withdrawn8-K
Shareholder vote8-K/A
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreementAgreement endedNew debt8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Auditor changed8-K/A
Auditor changed8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Sanuwave Health, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$2 MPrivate placement after listingUnder $2 million9debt, optionsSEC
Jan 2024$5 MPrivate placement after listing$2 to $10 million19debt, optionsSEC
Dec 2023$2 MPrivate placement after listingUnder $2 million15debt, optionsSEC
Jul 2023$3 MPrivate placement after listing$2 to $10 million17debt, optionsSEC
May 2023$1 MPrivate placement after listingUnder $2 million11debt, optionsSEC
Nov 2022$4 MPrivate placement after listing$2 to $10 million32debt, optionsSEC
Aug 2022$16 MPrivate placement after listing$10 to $50 million46debt, optionsSEC
Aug 2020$25 MPrivate placement after listing$10 to $50 million46equity, optionsSEC
Nov 2017$3 MPrivate placement after listing$2 to $10 million42debt, optionsSEC
Mar 2014$9 MPrivate placement after listing$2 to $10 million10equity, optionsSEC
Apr 2011$9 MNo. 1$2 to $10 million28equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Sanuwave Health, Inc. compares in Medical Devices

  • Market cap$44 M · higher than 24% of 142
  • Revenue$44 M · higher than 27% of 155
  • Net margin10.0% · higher than 71% of 144
  • Revenue growth35.0% · higher than 86% of 104
  • P/E ratio10.6× · lower than 89% of 47
  • Price / sales1.1× · lower than 80% of 96
  • Price / book27.2× · lower than 4% of 99
  • FCF yield4.4% · higher than 84% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Sanuwave Health, Inc.🇺🇸$44 M10.6×10.0%+35.0%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sanuwave Health, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sanuwave Health, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sanuwave Health, Inc.? Suggest a correction